ES2588155T3 - Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies - Google Patents

Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies Download PDF

Info

Publication number
ES2588155T3
ES2588155T3 ES09783664.7T ES09783664T ES2588155T3 ES 2588155 T3 ES2588155 T3 ES 2588155T3 ES 09783664 T ES09783664 T ES 09783664T ES 2588155 T3 ES2588155 T3 ES 2588155T3
Authority
ES
Spain
Prior art keywords
cdr
seq
depicted
single chain
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09783664.7T
Other languages
English (en)
Spanish (es)
Inventor
Peter Kufer
Tobias Raum
Roman Kischel
Ralf Lutterbüse
Patrick Hoffmann
Doris Rau
Susanne Mangold
Matthias Klinger
Evelyne Schaller
Susanne Hausmann
Petra Fluhr
Carola Steiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2588155(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Application granted granted Critical
Publication of ES2588155T3 publication Critical patent/ES2588155T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09783664.7T 2008-10-01 2009-10-01 Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies Active ES2588155T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185708P 2008-10-01 2008-10-01
US101857P 2008-10-01
PCT/EP2009/062793 WO2010037836A2 (en) 2008-10-01 2009-10-01 Cross-species-specific psmaxcd3 bispecific single chain antibody

Publications (1)

Publication Number Publication Date
ES2588155T3 true ES2588155T3 (es) 2016-10-31

Family

ID=42073956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09783664.7T Active ES2588155T3 (es) 2008-10-01 2009-10-01 Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies

Country Status (26)

Country Link
US (6) US20110293619A1 (enExample)
EP (3) EP3106468A1 (enExample)
JP (4) JP6126782B2 (enExample)
KR (1) KR101820535B1 (enExample)
CN (1) CN102171248B (enExample)
AU (1) AU2009299792B2 (enExample)
BR (1) BRPI0919841A2 (enExample)
CA (1) CA2738565C (enExample)
CY (1) CY1118303T1 (enExample)
DK (1) DK2356153T3 (enExample)
ES (1) ES2588155T3 (enExample)
HR (1) HRP20160684T1 (enExample)
HU (1) HUE030090T2 (enExample)
IL (1) IL212099A (enExample)
ME (1) ME02485B (enExample)
MX (1) MX2011003502A (enExample)
NZ (1) NZ591134A (enExample)
PL (1) PL2356153T3 (enExample)
PT (1) PT2356153T (enExample)
RS (1) RS54900B1 (enExample)
RU (1) RU2559531C2 (enExample)
SG (1) SG194398A1 (enExample)
SI (1) SI2356153T1 (enExample)
SM (1) SMT201600256B (enExample)
WO (1) WO2010037836A2 (enExample)
ZA (1) ZA201101067B (enExample)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150918A1 (en) * 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
ME02485B (me) * 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
EA201290020A1 (ru) 2009-05-19 2013-10-30 ЭйАйСи БЛЭБ КОМПАНИ Композитный токоприемник и способы его изготовления
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
SG190726A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
US8846042B2 (en) * 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
KR101870555B1 (ko) * 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013128027A1 (en) * 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
IN2015MN00139A (enExample) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
SMT201800335T1 (it) * 2012-11-06 2018-09-13 Bayer Pharma AG Formulazione di attivatori bispecifici per linfociti t (bite)
CN103087171B (zh) * 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
WO2014143886A2 (en) * 2013-03-15 2014-09-18 Edimer Pharmaceuticals, Inc. Anti-ectodysplasin antibodies
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3424952A1 (en) * 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
TN2017000532A1 (en) 2014-03-28 2019-04-12 Xencor Inc Bispecific antibodies that bind to cd38 and cd3.
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN106661119A (zh) 2014-07-01 2017-05-10 辉瑞公司 双特异性异二聚化双抗体及其用途
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
NZ734803A (en) 2015-01-23 2023-03-31 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016130819A2 (en) * 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016271113B2 (en) * 2015-05-29 2022-09-08 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
HUE048939T2 (hu) 2015-08-03 2020-09-28 Engmab Sarl Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN105198992B (zh) * 2015-10-16 2018-07-13 中国人民解放军海军总医院 一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用
JP2018534933A (ja) 2015-11-02 2018-11-29 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
CN108699136B (zh) * 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
PL3411404T3 (pl) * 2016-02-03 2023-02-13 Amgen Research (Munich) Gmbh Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
MX2018014228A (es) 2016-05-20 2019-08-12 Harpoon Therapeutics Inc Proteina de union de albumina sérica de dominio unico.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20240044520A (ko) * 2016-09-14 2024-04-04 테네오원, 인코포레이티드 Cd3 결합 항체
CN109952112B (zh) * 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
TWI676681B (zh) * 2017-03-29 2019-11-11 臺北醫學大學 具抗原專一性的t細胞及其用途
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
BR112020002013B1 (pt) 2017-08-03 2023-01-24 Amgen Inc Muteínas de il-21, método de preparação das mesmas, ácido nucleico, vetor, célula hospedeira, kit, uso dos mesmos e composição farmacêutica
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
SG11202001358RA (en) 2017-09-21 2020-03-30 Wuxi Biologics Ireland Ltd Novel anti-cd3epsilon antibodies
FI3694529T3 (fi) 2017-10-13 2024-09-17 Harpoon Therapeutics Inc Trispesifiset proteiinit ja niiden käyttömenetelmät
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
MA51631A (fr) 2018-01-12 2020-11-18 Amgen Inc Anticorps anti-pd1 et méthodes de traitement
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
MX2020010638A (es) 2018-04-11 2021-01-08 Inhibrx Inc Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados.
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
CN120285175A (zh) 2018-05-16 2025-07-11 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
US11746157B2 (en) * 2018-05-24 2023-09-05 Janssen Biotech, Inc. PSMA binding agents and uses thereof
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CA3102398A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
JP7651450B2 (ja) 2018-07-24 2025-03-26 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
US11976131B2 (en) 2018-07-31 2024-05-07 Heidelberg Pharma Research Gmbh Humanized antibodies against PSMA
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
US20210079115A1 (en) * 2019-04-19 2021-03-18 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
WO2020212947A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
EP4004208A1 (en) * 2019-07-26 2022-06-01 Ixaka France Aptamer-based multispecific therapeutic agents
ES2975528T3 (es) 2019-09-18 2024-07-08 Lamkap Bio Alpha AG Anticuerpos biespecíficos contra ceacam5 y cd3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
IL294461A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
BR112022013725A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Formulações para agentes terapêuticos proteicos
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
JP2023524875A (ja) 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
US20240043565A1 (en) * 2020-10-15 2024-02-08 Janux Therapeutics, Inc. Antibodies targeting psma and cd3 and uses thereof
IL302586A (en) * 2020-11-06 2023-07-01 Amgen Res Munich Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
PE20231860A1 (es) 2020-11-06 2023-11-21 Amgen Inc Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
TW202302636A (zh) 2021-02-16 2023-01-16 比利時商健生藥品公司 靶向ｂｃｍａ、ｇｐｒｃ５ｄ及ｃｄ３之三特異性抗體
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023011267A (es) 2021-03-24 2023-12-14 Janssen Biotech Inc Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
EP4330281A1 (en) 2021-04-29 2024-03-06 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
JP7707830B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707836B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707833B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707831B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707829B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707835B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707820B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707824B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707821B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707834B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707823B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707825B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707828B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707827B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707832B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
JP7707822B2 (ja) * 2021-10-06 2025-07-15 株式会社三洋物産 遊技機
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
CN118946583A (zh) 2022-03-21 2024-11-12 美国安进公司 用t细胞接合分子治疗前列腺癌的联合治疗方法
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
SE524615C2 (sv) 1999-06-30 2004-09-07 Volvo Personvagnar Ab Arrangemang för minskning av galvanisk korrosion mellan metallkomponenter
EP1210374B1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
JP4386776B2 (ja) * 2000-05-18 2009-12-16 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
WO2003064606A2 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
BRPI0407293A (pt) * 2003-02-06 2006-02-07 Micromet Ag Resposta duradoura da célula t
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
CN100509850C (zh) * 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK1716178T3 (da) * 2004-02-16 2010-09-20 Micromet Ag Mindre immunogene bindingsmolekyler
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
NZ552745A (en) * 2004-07-16 2009-01-31 Micromet Ag Expression-enhanced polypeptides
JP2006040495A (ja) 2004-07-30 2006-02-09 Renesas Technology Corp 半導体集積回路装置
NO20064183L (no) 2005-02-16 2006-11-08 Micromet Ag Mindre immunogene bindingsmolekyler
MX2007009878A (es) * 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20070065437A1 (en) 2005-09-12 2007-03-22 Greg Elson Anti-CD3 antibody formulations
CA2625440C (en) * 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US20100150918A1 (en) * 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
JP4970211B2 (ja) * 2007-10-18 2012-07-04 ヘキサゴン・メトロジー株式会社 ３次元形状測定器
ME02485B (me) * 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
WO2010037837A2 (en) 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
PL3411404T3 (pl) 2016-02-03 2023-02-13 Amgen Research (Munich) Gmbh Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T

Also Published As

Publication number Publication date
CA2738565C (en) 2023-10-10
EP3106468A1 (en) 2016-12-21
MX2011003502A (es) 2011-09-01
US20230037742A1 (en) 2023-02-09
SMT201600256B (it) 2016-08-31
JP6126782B2 (ja) 2017-05-10
PT2356153T (pt) 2016-07-15
SI2356153T1 (sl) 2016-07-29
ZA201101067B (en) 2013-03-27
SG194398A1 (en) 2013-11-29
WO2010037836A9 (en) 2011-05-05
EP2356153B1 (en) 2016-05-04
WO2010037836A3 (en) 2010-07-22
EP2356153A2 (en) 2011-08-17
CN102171248B (zh) 2015-07-15
US20210269550A1 (en) 2021-09-02
BRPI0919841A2 (pt) 2014-11-18
HRP20160684T1 (hr) 2016-07-15
US20210277143A1 (en) 2021-09-09
RU2011108687A (ru) 2012-11-10
RS54900B1 (sr) 2016-10-31
EP4180458A1 (en) 2023-05-17
US20110293619A1 (en) 2011-12-01
IL212099A0 (en) 2011-06-30
US20250163179A1 (en) 2025-05-22
US20190169310A1 (en) 2019-06-06
JP2018198595A (ja) 2018-12-20
ME02485B (me) 2017-02-20
DK2356153T3 (en) 2016-07-04
CY1118303T1 (el) 2017-06-28
NZ591134A (en) 2012-08-31
JP6643822B2 (ja) 2020-02-12
CA2738565A1 (en) 2010-04-08
RU2559531C2 (ru) 2015-08-10
AU2009299792B2 (en) 2015-07-16
AU2009299792A1 (en) 2010-04-08
US12281172B2 (en) 2025-04-22
CN102171248A (zh) 2011-08-31
HUE030090T2 (en) 2017-04-28
HK1158669A1 (zh) 2012-07-20
IL212099A (en) 2016-02-29
KR20110066195A (ko) 2011-06-16
JP2021164459A (ja) 2021-10-14
US11472886B2 (en) 2022-10-18
JP7273106B2 (ja) 2023-05-12
JP2016000736A (ja) 2016-01-07
JP2012504403A (ja) 2012-02-23
WO2010037836A2 (en) 2010-04-08
KR101820535B1 (ko) 2018-01-19
PL2356153T3 (pl) 2016-11-30

Similar Documents

Publication Publication Date Title
ES2588155T3 (es) Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies
ES2582603T3 (es) Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
US9587036B2 (en) Cross-species-specific PSMAxCD3 bispecific single chain antibody
ES2432792T3 (es) Dominio de unión a CD3-épsilon específico de especies cruzadas
EP2370467B1 (en) Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
ES2390243T3 (es) Agentes de unión biespecíficos específicos de especies cruzadas
WO2010037838A2 (en) Cross-species-specific single domain bispecific single chain antibody
HK1232556A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1232556A1 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1158669B (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1176366A (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1176366B (en) Cross-species-specific psmaxcd3 bispecific single chain antibody